Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma
- PMID: 22970007
- PMCID: PMC3438544
- DOI: 10.3892/etm.2012.515
Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma
Abstract
The aim of the present study was to screen for possible serum biomarkers for gastric adenocarcinoma. Surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS) was used to screen serum samples from 109 cases of gastric adenocarcinoma and 106 control subjects (60 healthy subjects, 30 patients with chronic superficial gastritis and 16 cases of chronic atrophic gastritis). The differentially expressed protein peaks were selected and isolated using high performance liquid chromatography (HPLC) and processed with enzyme prior to liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS) analysis and data mining with software XCalibur program components BioWorks 3.2. Among the gastric cancer cases, three differentially expressed protein peaks were selected as potential serum biomarkers: the m/z peaks at 5,906.5 showed increased expression (8.53±4.33 in the cancer group, and 0.88±0.31 in the control group); the m/z peaks at 6,635.7 and 8,716.3 showed decreased expression (6.54±2.44 and 0.93±0.29, respectively, in the cancer group and 17.56±4.43 and 2.16±0.98, respectively, in the control group) (P<0.01). The m/z peaks at 5,906.5, 6,635.7 and 8,716.3, were identified as fibrinogen α-chain, apolipo-protein A-II and apolipoprotein C-I. The combined use of the three biomarkers distinguished the cancer group patients from the control group samples at a sensitivity of 93.85% (61/65) and a specificity of 94.34% (50/53). In conclusion, fibrinogen α-chain, apolipoprotein A-II and apolipoprotein C-I were identified as potential markers for gastric cancer and appear to have diagnostic value for clinical applications.
Figures



Similar articles
-
Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS.Mol Med Rep. 2012 Jun;5(6):1531-5. doi: 10.3892/mmr.2012.834. Epub 2012 Mar 13. Mol Med Rep. 2012. PMID: 22427025
-
A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.Cancer Invest. 2006 Dec;24(8):747-53. doi: 10.1080/07357900601063873. Cancer Invest. 2006. PMID: 17162557
-
Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer.Jpn J Clin Oncol. 2010 Apr;40(4):336-42. doi: 10.1093/jjco/hyp175. Epub 2010 Jan 20. Jpn J Clin Oncol. 2010. PMID: 20089528
-
[Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].Zhonghua Zhong Liu Za Zhi. 2021 Nov 23;43(11):1188-1195. doi: 10.3760/cma.j.cn112152-20210315-00229. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34794222 Chinese.
-
The discovery and identification of a candidate proteomic biomarker of active tuberculosis.BMC Infect Dis. 2013 Oct 29;13:506. doi: 10.1186/1471-2334-13-506. BMC Infect Dis. 2013. PMID: 24168695 Free PMC article.
Cited by
-
Identification of carboxyl terminal peptide of Fibrinogen as a potential serum biomarker for gastric cancer.Tumour Biol. 2016 May;37(5):6963-70. doi: 10.1007/s13277-015-4394-y. Epub 2015 Dec 11. Tumour Biol. 2016. PMID: 26662807
-
Proteomic Analysis of Cerebrospinal Fluid From Patients With Extranodal NK-/T-Cell Lymphoma of Nasal-Type With Ethmoidal Sinus Metastasis.Front Oncol. 2020 Jan 10;9:1489. doi: 10.3389/fonc.2019.01489. eCollection 2019. Front Oncol. 2020. PMID: 31998645 Free PMC article.
-
Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches.Proteome Sci. 2014 Sep 24;12(1):47. doi: 10.1186/s12953-014-0047-0. eCollection 2014. Proteome Sci. 2014. PMID: 25298751 Free PMC article.
-
Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study.J Transl Med. 2015 Sep 17;13:304. doi: 10.1186/s12967-015-0668-9. J Transl Med. 2015. PMID: 26376850 Free PMC article.
-
Emerging blood-based biomarkers for detection of gastric cancer.World J Gastroenterol. 2015 Nov 7;21(41):11636-53. doi: 10.3748/wjg.v21.i41.11636. World J Gastroenterol. 2015. PMID: 26556992 Free PMC article. Review.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
-
- Tseng CW, Yang JC, Chen CN, et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics. 2011;11:2423–2439. - PubMed
-
- Kobayashi Y, Niwa Y, Tajika M, et al. Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer. Hepatogastroenterology. 2010;57:1631–1634. - PubMed
-
- Yang S, Chung HC. Novel biomarker candidates for gastric cancer. Oncol Rep. 2008;19:675–680. - PubMed
LinkOut - more resources
Full Text Sources